Fennec Pharmaceuticals is gaining steam in its quest for commercializing PEDMARK
Fennec Pharmaceuticals (NASDAQ: FENC), a small–stage biotechnology Company, announced the grant of a patent 10,596,190 entitled “Method for Reducing Ototoxicity in Pediatric Patients Receiving Platinum-Based Chemotherapy.” by the U.S. Patent and Trademark Office. The Company’s PEDMARK, which uses the patented technology, is a novel formulation...
